Course Summary
Contact Hour(s):
1.5 Contact Hours
Author:
Cindy Endicott (PT, DPT, FAAOMPT, ATC, Cert Dn)
This peer-reviewed course is applicable for the following professions:
Advanced Practice Registered Nurse (APRN), Athletic Trainer (AT/AL), CCI Credentialed Specialists, Certified Nurse Practitioner, Certified Registered Nurse Practitioner, Clinical Nurse Specialist (CNS), Licensed Practical Nurse (LPN), Licensed Vocational Nurses (LVN), Nursing Student, Occupational Therapist (OT), Occupational Therapist Assistant (OTA), Physical Therapist (PT), Physical Therapist Assistant (PTA), Registered Nurse (RN)
Accreditations:
The American Nurses Credentialing Center (ANCC), The American Occupational Therapy Association (AOTA), Board of Certification for Athletic Trainers (BOC)
State Approvals:
Alabama, Provider #ABNP1485; California BRN Provider #CEP # 13509; Florida Physical Therapy Association Approval: CE26-1195500; Kentucky Board of Nursing Provider #7-0085; Florida Board of Nursing Provider 50-353; New York State Education Department’s State Board for Physical Therapy
Course Description:
This course discusses principles of blood flow restriction training in rehabilitation, including safety considerations, patient screening, and populations in which blood flow restriction training might be utilized.
Outcomes:
≥ 92% of participants will know the basic concepts of blood flow restriction training (BFRT), patient safety considerations, and patient populations that may benefit from BFRT.
Objectives:
After completing this course, the learner will be able to:
1. Identify principles of muscle strengthening and hypertrophy.
2. Compare the benefits of blood flow restriction training (BFRT) to traditional resistance training.
3. Summarize the safety considerations related to BFRT.
4. Compare training parameters for typical types of exercise used with BFRT.
5. Outline conditions and patient populations that may benefit from BFRT.
Disclosures:
CEUFast Inc. and the course planning team for this educational activity do not have any relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.